In contrast, for patients with HoFH, if the combination of statin and ezetimibe plus a PCSK9 inhibitor is not sufficiently effective, treatment should include agents with LDL receptor-independent mechanisms of action, such as the microsomal transfer protein (MTP) inhibitor lomitapide or the angiopoietin-like protein 3 (ANGPTL3) inhibitor evinacumab, often in combination with selective LDL apheresis [15]. The gene discussed is ANGPTL3; the disease is homozygous familial hypercholesterolemia.